Differences of SGOT-SGPT Levels in Serum and EDTA Plasma in Hepatitis B Patients

Abstract

Hepatitis is a disorder in liver inflammation that can be caused by infection with parasites, protozoa, bacteria, viruses, metabolic disorders, drugs, and alcohol that causes damage to human liver cells and can attack all ages, genders, and races throughout the world. Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT) levels in EDTA plasma can tend to increase more than serum. It is because EDTA plasma contains coagulation factors that can interfere with examining SGOT and SGPT levels on the device. In contrast, serum consists of proteins, electrolytes, antibodies, antigens, and hormones that do not contain coagulation factors. This study aims to compare SGOT and SGPT levels on serum and EDTA plasma samples in Hepatitis B patients. This type of research is an experimental study. This research was conducted on 35 hepatitis B specimens and then tested using the enzymatic method with Humastar 100 (spectrophotometry). Abnormal SGOT levels (>27 U/L) were 54.3% in serum and 51.4% in plasma EDTA. Abnormal SGPT levels (>34 U/L) were 22.9% in serum and 25.7% in plasma EDTA, so there is an insignificant difference in SGOT and SGPT levels in EDTA serum and plasma samples.

Keywords

• edta plasma
• hepatitis b
• serum
• erum glutamic oxaloacetic transaminase-sgot
• serum glutamic pyruvic transaminase-sgpt